WallStreetZenWallStreetZen

NASDAQ: AMRX
Amneal Pharmaceuticals Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Amneal Pharmaceuticals earnings were $72.1M for the trailing 12 months ending Dec 31, 2025, with N/A growth year over year. The latest AMRX earnings report on Dec 31, 2025 announced Q4 2025 earnings of $35.1M, up 1,380.6% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, AMRX reported annual earnings of $72.1M, with -161.6% growth. The next AMRX earnings date is May 1, 2026.

AMRX past earnings growth

How has AMRX's earnings growth performed historically?

Company
N/A
Industry
53.44%
Market
87.13%
AMRX's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
AMRX's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance

AMRX earnings history

Current Revenue
$3.0B
Current Earnings
$72.1M
Current Profit Margin
2.4%

AMRX Return on Equity

Current Company
-68%
Current Industry
13.7%
Current Market
29.4%
AMRX's Return on Equity (-68%)... subscribe to Premium to read more.
High Return on Equity Performance

AMRX Return on Assets

Current Company
2%
Current Industry
5.5%
AMRX is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when AMRX announces earnings.

AMRX Return on Capital Employed

Current Company
11.6%
Current Industry
11.7%
AMRX has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

AMRX vs Pharmaceutical Stocks

TickerEBITDAEarningsY/Y EarningsEPS
AMRX$548.00M$72.06M-17.99%$0.23
INDV$304.00M$210.00M+4.48%$1.68
PBH$346.27M$186.50M+2.85%$3.81
ALKS$330.89M$241.66M-17.12%$1.47
SUPN$50.51M-$38.55MN/A-$0.68
View Top Pharmaceutical Stocks

AMRX earnings dates

Next earnings date
May 1, 2026

Amneal Pharmaceuticals Earnings Reports & History FAQ

What were Amneal Pharmaceuticals's earnings last quarter?

On AMRX's earnings call on Invalid Date, Amneal Pharmaceuticals (NASDAQ: AMRX) reported Q4 2025 earnings per share (EPS) of $0.11, up 210% year over year. Total AMRX earnings for the quarter were $35.08 million. In the same quarter last year, Amneal Pharmaceuticals's earnings per share (EPS) was -$0.10.

If you're new to stock investing, here's how to buy Amneal Pharmaceuticals stock.

When does Amneal Pharmaceuticals report earnings?

The next AMRX earnings date is Invalid Date. Add AMRX to your watchlist to be reminded of Amneal Pharmaceuticals's next earnings date.

Is Amneal Pharmaceuticals profitable or losing money?

As of the last Amneal Pharmaceuticals earnings report, Amneal Pharmaceuticals is currently profitable. Amneal Pharmaceuticals's net profit (also called net income) for the twelve months ending Dec 31, 2025 was $72.06 million, a 161.65% decrease year over year.

What was AMRX's earnings growth in the past year?

As of Amneal Pharmaceuticals's earnings date in Invalid Date, Amneal Pharmaceuticals's earnings has grown year over year. AMRX earnings in the past year totalled $72.06 million.

What are Amneal Pharmaceuticals's earnings expectations?

The current EPS estimate for Amneal Pharmaceuticals's earnings report in Invalid Date is $0.19.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.